In News 

     The drug, lecanemab, jointly developed by pharma companies Biogen and Eisai, was tested on patients with early Alzheimer’s. 

    About Lecanemab 

    • Lecanemab belongs to a class of drugs called monoclonal antibodies. 
    • These antibody-mediated drugs target beta-amyloid, the protein deposition that is seen in patients with Alzheimer’s disease, and disrupts cell function.
    • Lecanemab appears to have shown modest effects in early dementia both via clinical improvements (scores in the CDR and ADAS-Cog rating scales) and reduction in amyloid plaques.